临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 65-23-6

Pyridoxine

中文名称:维生素B6
CAS号:65-23-6
分子式: C8H11NO3 分子量: 169.18
产品形式: free base
研发状态: Not yet recruiting
研发用途: Dietary Exposure; Diabetes Mellitus Type 2; Cardiovascular Diseases; Bone Loss; Sustainability; Exposure; Obesity; Vitamin Deficiency; Mineral Deficiency
研究机构: German Federal Institute for Risk Assessment; Max Rubner-Institut; University of Bonn; Research Institute for Plant-Based Nutrition; University of Jena; University of Regensburg; Heidelberg University; University of Vienna
研发日期: April 1 2024
研发阶段: --
Pyridoxine (Pyridoxol, Vitamin B6, Gravidox), also known as vitamin B6, is a form of vitamin B6 found commonly in food and used as dietary supplement. It is a cofactor for both glutamic acid decarboxylase and GABA transaminase.

CAS: 65-22-5

Pyridoxal hydrochloride

中文名称:吡哆醛盐酸盐
CAS号:65-22-5
分子式: C8H10ClNO3 分子量: 203.62
产品形式: Free Base
研发状态: Recruiting
研发用途: Prader-Willi Syndrome
研究机构: Harmony Biosciences LLC
研发日期: April 30 2024
研发阶段: Phase 3
Pyridoxal hydrochloride (HQ) is an active endogenous metabolite.

CAS: 65141-46-0

Nicorandil

中文名称:尼可地尔
CAS号:65141-46-0
分子式: C8H9N3O4 分子量: 211.17
产品形式: free base
研发状态: Active not recruiting
研发用途: Chronic Stable Angina
研究机构: Auxilius Pharma sp.z.o.o.
研发日期: November 27 2023
研发阶段: Early Phase 1
Nicorandil (SG-75) is a potassium channel activator, and stimulates guanylate cyclase to increase formation of cyclic GMP (cGMP).

CAS: 649735-63-7

Brivanib Alaninate (BMS-582664)

中文名称:丙氨酸布立尼布
CAS号:649735-63-7
分子式: C22H24FN5O4 分子量: 441.46
产品形式: Alaninate
研发状态: Completed
研发用途: Solid Tumors
研究机构: Bristol-Myers Squibb
研发日期: Oct-07
研发阶段: Phase 1
Brivanib alaninate (BMS-582664) is the prodrug of BMS-540215, an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM.

CAS: 649735-46-6

Brivanib (BMS-540215)

中文名称: 布立尼布
CAS号:649735-46-6
分子式: C19H19FN4O3 分子量: 370.38
产品形式: free base
研发状态: Unknown status
研发用途: Ovarian Cancer
研究机构: Hunan Cancer Hospital
研发日期: January 14 2019
研发阶段: Phase 1
Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3.

CAS: 64887-14-5

Urapidil HCl

中文名称:盐酸乌拉地尔
CAS号:64887-14-5
分子式: C20H29N5O3.HCl 分子量: 423.94
产品形式: Hydrochloride
研发状态: Unknown status
研发用途: Anesthesia
研究机构: Nan Jiang; First Affiliated Hospital Sun Yat-Sen University
研发日期: January 1 2016
研发阶段: Not Applicable
Urapidil HCl is a hydrochloride salt form of urapidil which is α1-adrenoceptor antagonist and 5-HT1A receptor agonist with pIC50 of 6.13 and 6.4 respectively.